Transaction values Ignite Proteomics at approximately $150 million and is expected to position Ignite as an independent NYSE-listed functional proteomics company, while Aditxt continues as a separate Nasdaq-listed
Registry expected to pair Ignite's reimbursed RPPA platform with structured outcomes tracking across ADC and immunotherapy regimens; initiative expected to generate an estimated ~$13 million for Ignite over the course
Seasoned executive who founded and built an NYSE-listed healthcare real estate company to over $1 billion in enterprise value — delivering an average dividend yield of approximately 8.5% to shareholders — brings capital
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-27 reverse split of its common stock.
Peer-reviewed study finds standard HER2 IHC testing shows limited predictive value for T-DXd while Ignite's platform — the only commercially available multiplex assay in the study—demonstrates predictive value for
Busch brings public company leadership and capital markets experience to support Ignite's next phase of growth
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating
Ignite plans to launch a new program in 2026 supporting treatment selection for more than 600,000 people in the United States living with metastatic cancer and limited therapeutic options.
Aditxt, Inc. (NASDAQ:ADTX)
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-8 reverse split of its common stock. Commencing
Aditxt has filed a preliminary proxy statement seeking shareholder approval for employee stock purchase plan, company name change, and other proposals
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, announced today that it will effect a 1-for-113 reverse split of its common stock.
Prospective study to evaluate diagnostic performance and generate real-world data for the Mitomic® Endometriosis Test, a non-invasive alternative to surgical diagnosis for endometriosis
Aditxt, Inc. (NASDAQ:ADTX)
-- Evofem Shareholders Did Not Approve the Merger with Aditxt --
-- Evofem Pivots to Target National Listing for Stock, Growth Capital to Catalyze Net Sales --
SAN DIEGO, Oct. 20, 2025 /PRNewswire/ -- Evofem
-- 130% increase in traffic to PHEXXI.com, the website for Evofem's hormone-free prescription contraceptive PHEXXI® (lactic acid citric acid and potassium bitartrate) --
-- PHEXXI® is #1 most followed
-- Special Meeting to be held on September 26, 2025 --
SAN DIEGO, Sept. 9, 2025 /PRNewswire/ -- In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID:
Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026
Aditxt, Inc. (NASDAQ:ADTX) ("Aditxt", or the "Company"), a social innovation
